{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:41:13Z","timestamp":1791265273141,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Argentina S.A.","award":["Brigatinib-5008"],"award-info":[{"award-number":["Brigatinib-5008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40801-025-00484-z","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T20:56:02Z","timestamp":1740603362000},"page":"227-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04887519","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Claudio","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Ileana","family":"Malcervelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gast\u00f3n Lucas","family":"Martinengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Levit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Servienti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Malaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Brion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Patronella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2580-4306","authenticated-orcid":false,"given":"Andrea","family":"Zum\u00e1rraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Zarba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"484_CR1","unstructured":"National Cancer Institute Argentina. About cancer, statistics 2020. Available from: https:\/\/www.argentina.gob.ar\/salud\/instituto-nacional-del-cancer\/estadisticas\/incidencia. Accessed 12 Jan 2024."},{"issue":"1","key":"484_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/1758834015617355","volume":"8","author":"I Sullivan","year":"2016","unstructured":"Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016;8(1):32\u201347. https:\/\/doi.org\/10.1177\/1758834015617355.","journal-title":"Ther Adv Med Oncol."},{"issue":"11","key":"484_CR3","doi-asserted-by":"publisher","first-page":"10033","DOI":"10.3390\/curroncol30110729","volume":"30","author":"C Gridelli","year":"2023","unstructured":"Gridelli C, Tiseo M, Cortinovis DL, Migliorino MR, Barbieri V, Bironzo P, et al. Sharing experience with anaplastic lymphoma kinase tyrosine kinase inhibitors in lung cancer: an Italian Expert Panel Discussion. Curr Oncol. 2023;30(11):10033\u201342. https:\/\/doi.org\/10.3390\/curroncol30110729.","journal-title":"Curr Oncol"},{"issue":"8","key":"484_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s40262-023-01284-w","volume":"62","author":"N Gupta","year":"2023","unstructured":"Gupta N, Hanley MJ, Griffin RJ, Zhang P, Venkatakrishnan K, Sinha V. Clinical pharmacology of brigatinib: a next-generation anaplastic lymphoma kinase inhibitor. Clin Pharmacokinet. 2023;62(8):1063\u201379. https:\/\/doi.org\/10.1007\/s40262-023-01284-w.","journal-title":"Clin Pharmacokinet"},{"key":"484_CR5","unstructured":"Alunbrig\u00ae (brigatinib): full prescribing information. Revised 02\/2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208772s013lbl.pdf. Accessed 31 Dec 2023."},{"issue":"22","key":"484_CR6","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.71.5904.","journal-title":"J Clin Oncol"},{"issue":"10","key":"484_CR7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40265-017-0776-3","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Brigatinib: first global approval. Drugs. 2017;77(10):1131\u20135. https:\/\/doi.org\/10.1007\/s40265-017-0776-3.","journal-title":"Drugs"},{"issue":"21","key":"484_CR8","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1810171.","journal-title":"N Engl J Med"},{"issue":"2","key":"484_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40265-020-01449-y","volume":"81","author":"SM Hoy","year":"2021","unstructured":"Hoy SM. Brigatinib: A review in ALK-inhibitor na\u00efve advanced ALK-positive NSCLC. Drugs. 2021;81(2):267\u201375. https:\/\/doi.org\/10.1007\/s40265-020-01449-y.","journal-title":"Drugs"},{"issue":"12","key":"484_CR10","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","volume":"18","author":"JC Yang","year":"2023","unstructured":"Yang JC, Liu G, Lu S, He J, Burotto M, Ahn MJ, et al. Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial. J Thorac Oncol. 2023;18(12):1743\u201355. https:\/\/doi.org\/10.1016\/j.jtho.2023.08.010.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"484_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jtho.2020.02.011","volume":"15","author":"TL Ng","year":"2020","unstructured":"Ng TL, Narasimhan N, Gupta N, Venkatakrishnan K, Kerstein D, Camidge DR, et al. Early-onset pulmonary events associated with brigatinib use in advanced NSCLC. J Thorac Oncol. 2020;15(7):1190\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2020.02.011.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"484_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100738","volume":"45","author":"V Ke\u015f","year":"2021","unstructured":"Ke\u015f V, S\u00fctc\u00fco\u011flu O, G\u00fcrler F, Yaz\u0131c\u0131 O, \u00d6zet A. Brigatinib-induced tuberculosis reactivation: a case report. Curr Probl Cancer. 2021;45(6): 100738. https:\/\/doi.org\/10.1016\/j.currproblcancer.2021.100738.","journal-title":"Curr Probl Cancer"},{"issue":"8","key":"484_CR13","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/ckj\/sfac062","volume":"15","author":"M Bonilla","year":"2022","unstructured":"Bonilla M, Jhaveri KD, Izzedine H. Anaplastic lymphoma kinase inhibitors and their effect on the kidney. Clin Kidney J. 2022;15(8):1475\u201382. https:\/\/doi.org\/10.1093\/ckj\/sfac062.","journal-title":"Clin Kidney J"},{"issue":"12","key":"484_CR14","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","volume":"17","author":"SN Gettinger","year":"2016","unstructured":"Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17(12):1683\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(16)30392-8.","journal-title":"Lancet Oncol"},{"issue":"9","key":"484_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/oncolo\/oyac116","volume":"27","author":"M Jahanzeb","year":"2022","unstructured":"Jahanzeb M, Lin HM, Wu Y, Zhang P, Gorritz M, McGuiness CB, et al. Real-world efficacy and tolerability of brigatinib in patients with non-small cell lung cancer with prior ALK-TKIs in the United States. Oncologist. 2022;27(9):790\u20138. https:\/\/doi.org\/10.1093\/oncolo\/oyac116.","journal-title":"Oncologist"},{"key":"484_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lungcan.2021.05.017","volume":"157","author":"S Popat","year":"2021","unstructured":"Popat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, Griesinger F, et al. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 2021;157:9\u201316. https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.017.","journal-title":"Lung Cancer"},{"key":"484_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2019.08.010","volume":"136","author":"R Descourt","year":"2019","unstructured":"Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, et al. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: a multicentric real-world study (BRIGALK study). Lung Cancer. 2019;136:109\u201314. https:\/\/doi.org\/10.1016\/j.lungcan.2019.08.010.","journal-title":"Lung Cancer"},{"issue":"7","key":"484_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000787","volume":"30","author":"M Hochmair","year":"2019","unstructured":"Hochmair M, Weinlinger C, Schwab S, Naber J, Setinek U, Krenbek D, et al. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. Anticancer Drugs. 2019;30(7): e0787. https:\/\/doi.org\/10.1097\/CAD.0000000000000787.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"484_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17305\/bjbms.2021.5859","volume":"22","author":"A Patcas","year":"2022","unstructured":"Patcas A, Chis AF, Militaru CF, Bordea IR, Rajnoveanu R, Coza OF, et al. An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance. Bosn J Basic Med Sci. 2022;22(1):1\u201313. https:\/\/doi.org\/10.17305\/bjbms.2021.5859.","journal-title":"Bosn J Basic Med Sci"},{"issue":"1","key":"484_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41698-021-00239-3","volume":"5","author":"AK Angeles","year":"2021","unstructured":"Angeles AK, Christopoulos P, Yuan Z, Bauer S, Janke F, Ogrodnik SJ, et al. Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. NPJ Precis Oncol. 2021;5(1):100. https:\/\/doi.org\/10.1038\/s41698-021-00239-3.","journal-title":"NPJ Precis Oncol."},{"issue":"2","key":"484_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2217\/fon-2020-0747","volume":"17","author":"D Heredia","year":"2021","unstructured":"Heredia D, Barr\u00f3n F, Cardona AF, Campos S, Rodriguez-Cid J, Martinez-Barrera L, et al. Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP). Future Oncol. 2021;17(2):169\u201381. https:\/\/doi.org\/10.2217\/fon-2020-0747.","journal-title":"Future Oncol"},{"issue":"12","key":"484_CR22","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1007\/s10147-022-02232-7","volume":"27","author":"S Sugawara","year":"2022","unstructured":"Sugawara S, Kondo M, Yokoyama T, Kumagai T, Nishio M, Goto K, et al. Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study. Int J Clin Oncol. 2022;27(12):1828\u201338. https:\/\/doi.org\/10.1007\/s10147-022-02232-7. (Erratum.In:IntJClinOncol.2022Oct16;Erratumin:IntJClinOncol.2023May;28(5):724-5).","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"484_CR23","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1111\/cas.15888","volume":"114","author":"T Yoshida","year":"2023","unstructured":"Yoshida T, Kumagai T, Toyozawa R, Katayama R, Nishio M, Seto T, et al. Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: final results of the phase 2 J-ALTA trial. Cancer Sci. 2023;114(9):3698\u2013707. https:\/\/doi.org\/10.1111\/cas.15888. (Erratum.In:CancerSci.2023Dec;114(12):4776-7).","journal-title":"Cancer Sci"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00484-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00484-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00484-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T03:08:20Z","timestamp":1750129700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00484-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00484-z","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"30 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Takeda Argentina S.A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Claudio Martin received consulting fees from Pfizer, Astra Zeneca, Takeda, Boehringer Ingelheim and Roche. Gabriela Ileana Malcervelli received travel support and consulting fees from Takeda. Lucas Gast\u00f3n Martinengo has no conflict of interest that are directly relevant to the content of this article. Patricio Servienti received travel support from Raffo, GSK, Takeda, Merck, BMS and Pfizer; lecture fees from GSK and Raffo; and consulting fees from Pfizer. Patricio Levit received lectures fees from Roche, Takeda and AstraZeneca, and consulting fees from Tuteur. Elisa Malaver, Laura Brion, Vanesa Patronella and Andrea Zumarr\u00e1ga are employees of Takeda Argentina S.A. Jose Zarba received travel support from MSD, BMS and Takeda; lecture fees from Novartis, BMS and MSD; and consulting fees from MSD, Takeda and AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study protocol (Brigatinib-5008) was approved by an independent ethics committee (Fundaci\u00f3n de Estudios Farmacol\u00f3gicos y Medicamentos, FEFyM) on 21 October, 2020. All patients were required to provide mandatory written informed consent. Good pharmacoepidemiology practice guidelines, local applicable regulations and the Declaration of Helsinki were followed. Furthermore, this study conformed to all regulations concerning the use of personal data. The study was incorporated in the clinical study registry of the city of Buenos Aires, Argentina (PRIISA-BA #3201) and in ClinicalTrials.gov (NCT04887519).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"To receive brigatinib during the post-marketing surveillance study period, eligible patients were required to provide a written inform consent in the presence of the treating physician. The patients were informed about the medication and the scope of the study before providing their consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets, including the redacted study protocol, redacted statistical analysis plan and individual participant data supporting the results reported in this article, will be made available within 3 months from initial request to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection and requirements for consent and anonymization.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"CM, GIM, LGM, PS, PL and JZ participated in patient recruitment and data collection. EM, LB, VP, AZ and JZ participated in study design. All authors participated in the analysis and interpretation of data and contributed to writing and critical revision of all drafts.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}